NCT06829641Not yet recruiting
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
A Multicenter Real-World Data Pooled Analysis: The Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
Source: ClinicalTrials.gov · Last updated 27 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were enrolled, with treatment modalities and clinical outcomes of stage III non-small cell lung cancer (NSCLC) patients from multiple tertiary hospitals in real-world settings since August 2020 being collected and analyzed.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 9 Feb 2025
- Start date
- 9 Aug 2025
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- West China Hospital
- Diseases
- Lung cancer
- NCT number
- NCT06829641
What you commit to
- Study type: Observational
- Planned participants: 200
- From 9 Aug 2025 to the primary completion date, 1 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.
- Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.
Other illness
- Patients with other previous malignancies did not require additional treatment. Patients with incomplete key baseline and treatment information:including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant.
Who the study is looking for
- Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.
- Patients were negative for EGFR-sensitive mutations or ALK/ROS1 fusion alterations.
- No prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered.
- ECOG PS scores of the enrolled patients ranged from 0 to 2.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.